Search results for "AGENT"

showing 10 items of 8904 documents

Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder

2013

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 d…

medicine.medical_specialtyCYP2D6Venlafaxine HydrochlorideVenlafaxineCYP2C19Severity of Illness IndexGastroenterologyAnti-Infective AgentsInternal medicineTremorTrimethoprim Sulfamethoxazole Drug CombinationHumansMedicineDrug InteractionsPharmacology (medical)PsychiatryCYP2C9PharmacologyDepressive Disorder MajorCYP3A4business.industryVenlafaxine HydrochlorideMiddle AgedCyclohexanolsmedicine.diseaseTrimethoprimCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Major depressive disorderFemaleAryl Hydrocarbon HydroxylasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth

2007

This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 microg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 microg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 microg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in r…

medicine.medical_specialtyCancer ResearchPeripheral neuropathyNeural ConductionNeurophysiologyAntineoplastic AgentsHindlimbHematocritNeuroprotectionAntineoplastic AgentInternal medicinemedicinePathologyAnimalsRats WistarErythropoietinCisplatincisplatin; Erythropoietin; peripheral neuropathy; tumor growthmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnimalNeurotoxicityPeripheral Nervous System DiseasesMammary Neoplasms ExperimentalTumour growthHematologymedicine.diseaseRatsHindlimbDose–response relationshipPeripheral neuropathyEndocrinologyOncologyHematocritErythropoietinRatFemalePeripheral Nervous System DiseaseCisplatinbusinessCell Divisionmedicine.drug
researchProduct

Acute and Chronic Captopril, but Not Prazosin or Nifedipine, Normalize Alterations in Adrenergic Intracellular Ca2+ Handling Observed in the Mesenter…

2004

The effect of hypertension and acute (36-h) or chronic (from age 6 to 16 weeks) antihypertensive treatment with prazosin (2 mg kg(-1) per day), nifedipine (50 mg kg(-1) per day), or captopril (50 mg kg(-1) per day) on Ca2+ mobilization due to alpha1-adrenoceptor activation was analyzed in functional studies using arterial rings [four conductance/distributing vessels: aorta, main mesenteric, iliac, and tail arteries and two resistance vessels; first and second small mesenteric artery branches obtained from spontaneously hypertensive rats (SHR, 6 and 16 weeks old) and age-matched Wistar Kyoto rats (WKY)]. Maximal response to noradrenaline in the presence of extracellular Ca2+ is not affected …

medicine.medical_specialtyCaptoprilSympathetic Nervous SystemNifedipineAdrenergicAngiotensin-Converting Enzyme InhibitorsBlood PressureRats Inbred WKYMuscle Smooth VascularNorepinephrineNifedipineRats Inbred SHRInternal medicinemedicine.arteryPrazosinAnimalsVasoconstrictor AgentsMedicineMesenteric arteriesAdrenergic alpha-AntagonistsPharmacologyAortabusiness.industryCaptoprilPrazosinCalcium Channel BlockersMesenteric ArteriesRatsEndocrinologyBlood pressuremedicine.anatomical_structurecardiovascular systemMolecular MedicineCalciumbusinessMuscle Contractionmedicine.drugArteryJournal of Pharmacology and Experimental Therapeutics
researchProduct

Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine.

1996

Abstract 1. The effects of SR 48692 on neurotensin (NT)-induced mechanical responses were investigated in rat duodenum and proximal colon by use of isometric, isovolumic preparations. 2. SR 48692 inhibited the relaxant responses to NT in duodenal circular and longitudinal muscle. It also antagonized the NT-induced contractile effects in duodenal circular muscle and in proximal colon (both muscular layers). 3. From Schild analysis and pA2 value for SR 48692 was 8.2 in tissues where NT induced relaxant effects and 7.5 in tissues where NT induced contractile effects and the slope of the regression line was not significantly different from unity, indicating competitive antagonism. 4. SR 48692 d…

medicine.medical_specialtyCarbacholColonDuodenumMuscle RelaxationNeuropeptideSubstance PBiologyPeptide hormoneIn Vitro Techniqueschemistry.chemical_compoundNorepinephrineInternal medicineIsometric ContractionmedicineAnimalsReceptors NeurotensinVasoconstrictor AgentsRats WistarReceptorNeurotensinPharmacologyMuscle SmoothRatsMuscle relaxationmedicine.anatomical_structureEndocrinologychemistryDuodenumQuinolinesPyrazolesmedicine.drugNeurotensinResearch ArticleBritish journal of pharmacology
researchProduct

Alterations on AChE Activity of the Fish Anguilla anguilla as Response to Herbicide-Contaminated Water

2000

Abstract The inhibition of both total and specific acetylcholinesterase activities was measured in the whole eyes of the yellow eel Anguilla anguilla after exposure to the carbamate thiobencarb. In vivo assays were conducted under a constant flow-through system of thiobencarb-contaminated water (1/60 LC50 96 h=0.22 ppm for 96 h) followed by a recovery period in clean water (192 h more). The results indicated a measurable level of AChE activity on eyes of control eels, which resulted in a sensitive indicator of the presence of thiobencarb in the water. The pesticide induced significant inhibitory effects on AChE activity ranging from 35% in total AChE activity to 75% in specific AChE activit…

medicine.medical_specialtyCarbamateAchéHealth Toxicology and Mutagenesismedicine.medical_treatmentAnticholinergic agentsBiologychemistry.chemical_compoundThiocarbamatesAnguillidaeInternal medicinemedicineAnimalsCholinesteraseEelsHerbicidesPublic Health Environmental and Occupational HealthGeneral MedicineAnatomybiology.organism_classificationPollutionAcetylcholinesteraselanguage.human_languageEnzyme assayEndocrinologychemistryToxicityAcetylcholinesteraselanguagebiology.proteinCholinesterase InhibitorsWater Pollutants ChemicalEcotoxicology and Environmental Safety
researchProduct

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

2021

ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk fac…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineantiviral therapymedicineHumansPropensity Scoreantiviral therapy; hepatocellular carcinoma; meta-analysisbusiness.industryLiver NeoplasmsGastroenterologyAntiviral therapyPatient datahepatocellular carcinomamedicine.disease3. Good healthmeta-analysis030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinomaRelative riskCohort030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeoplasm Recurrence LocalbusinessDirect acting
researchProduct

Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk

2017

BACKGROUND In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy. METHODS A selective search for pertinent literature was carried out in the PubMed database with the search t…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusReview Articlemedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciencesDrug treatment0302 clinical medicineChronic hepatitisRisk FactorsInterferonInternal medicinemedicineHumansbusiness.industryIncidence (epidemiology)Liver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesTumor progression030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusinessmedicine.drugDeutsches Ärzteblatt international
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

Feasibility and Diagnostic Impact of Fluorescence-Based Diagnostic Laparoscopy in Hepatocellular Carcinoma: A Case Report

2002

Fluorescence-based diagnostic techniques are an evolving field in the staging of hepatologic and gastroenterologic malignancies. The method aims at improved accuracy in the detection of locoregional and distant metastases. In hepatocellular carcinoma, detection of metastases is of utmost importance, because advanced tumors preclude curative surgical therapy. We present here our first experience of fluorescence-based diagnostic laparoscopy in a patient with hepatocellular carcinoma. We performed diagnostic laparoscopy in a 76-year-old woman who presented with a tumor of the liver and increased serum levels of alpha-fetoprotein. For photosensitization, 5-aminolevulinic acid (20 mg/kg bodyweig…

medicine.medical_specialtyCarcinoma HepatocellularLightDiagnostic laparoscopyFluorescenceMetastasisLight sourceHumansMedicineNeoplasm MetastasisLaparoscopyAgedNeoplasm StagingHistological examinationPhotosensitizing Agentsmedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyAminolevulinic Acidmedicine.diseaseEndoscopySurgeryTransplantationHepatocellular carcinomaFemaleLaparoscopyRadiologybusinessEndoscopy
researchProduct

Dofetilide effects on the inhibition by trains of subthreshold conditioning stimuli.

2004

We investigated the electrophysiological actions of dofetilide upon the ventricular myocardium to determine whether the drug modifies the inhibitory effects of subthreshold stimuli trains upon ventricular refractoriness. In nine Langendorff perfused rabbit hearts, ventricular epicardial electrodes were used to determine the following parameters at baseline and during dofetilide perfusion (0.5 micromolar): effective (ERP) and functional (FRP) refractory periods, conduction velocity (CV), wavelength (WL), and ERP prolongation (inhibitory effect) induced by subthreshold stimuli trains (STr) at pulse frequencies of 100, 300, and 600 Hz. Dofetilide significantly prolongs ventricular refractorine…

medicine.medical_specialtyCardiac Complexes PrematureRefractory Period ElectrophysiologicalHeart VentriclesDofetilideStimulationInhibitory postsynaptic potentialNerve conduction velocityElectrocardiographyHeart Conduction SystemInternal medicinePhenethylaminesmedicinePotassium Channel BlockersAnimalsSulfonamidesDose-Response Relationship DrugSubthreshold conductionPulse (signal processing)business.industryCardiac Pacing ArtificialGeneral MedicineElectric StimulationElectrophysiologyAnesthesiaModels AnimalCardiologyRabbitsCardiology and Cardiovascular MedicinebusinessPerfusionAnti-Arrhythmia Agentsmedicine.drugPacing and clinical electrophysiology : PACE
researchProduct